Format

Send to

Choose Destination
J Cutan Med Surg. 2014 May-Jun;18(3):151-5.

Efinaconazole 10% nail solution: a new topical treatment with broad antifungal activity for onychomycosis monotherapy.

Abstract

BACKGROUND:

Topical therapies for onychomycosis are associated with less adverse events than systemic therapies, but poor nail penetration limits their efficacy. Consequently, an efinaconazole 10% nail solution was developed.

OBJECTIVE:

To review the evidence supporting the usefulness of efinaconazole monotherapy in onychomycosis management.

METHODS:

PubMed and clinicaltrials.gov databases and abstracts from the 2013 annual meeting of the American Academy of Dermatology were searched in April 2013 using the terms "efinaconazole," "IDP-108," and "KP-103."

RESULTS:

In vitro, efinaconazole possesses a broad antifungal activity similar or superior to that of other antifungals. Its low affinity for keratin results in good nail penetration. Efinaconazole 10% nail solution administered daily for 36 or 48 weeks to treat mild to moderate toenail onychomycosis caused by dermatophytes results in complete and mycologic cure rates of 15 to 25% and 53 to 87%, respectively. No serious skin reaction is associated with its use.

CONCLUSION:

Efinaconazole 10% nail solution is a promising new treatment for onychomycosis.

PMID:
24800702
DOI:
10.2310/7750.2013.13095
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center